```
Uploading 09769450.str

L1      STRUCTURE UPLOADED

=> s sss sam l1
SAMPLE SEARCH INITIATED 14:42:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  14361 TO ITERATE

  7.0% PROCESSED    1000 ITERATIONS                          50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:      280051 TO   294389
PROJECTED ANSWERS:          73816 TO    81282

L2           50 SEA SSS SAM L1

=>
Uploading 09769450b.str

L3      STRUCTURE UPLOADED

=> s sss sam l3
SAMPLE SEARCH INITIATED 14:47:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    592 TO ITERATE

100.0% PROCESSED     592 ITERATIONS                          39 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       10381 TO    13299
PROJECTED ANSWERS:            406 TO     1154

L4           39 SEA SSS SAM L3

=> s sss full l3
FULL SEARCH INITIATED 14:48:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  11663 TO ITERATE

100.0% PROCESSED   11663 ITERATIONS                        1047 ANSWERS
SEARCH TIME: 00.00.01

L5         1047 SEA SSS FUL L3

=> file caplus medline
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              152.15     152.36

FILE 'CAPLUS' ENTERED AT 14:48:28 ON 13 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 14:48:28 ON 13 JUN 2003

=> s l5
L6         199 L5

=> s l6 and kappa
```

```
L7          113 L6 AND KAPPA

=> s l7 and py<= 1996
L8           58 L7 AND PY<= 1996

=> s l8 and pruritus
L9            0 L8 AND PRURITUS

=> duplicate remove l8
DUPLICATE PREFERENCE IS 'CAPLUS, MEDLINE'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L8
L10          44 DUPLICATE REMOVE L8 (14 DUPLICATES REMOVED)
```

L10 ANSWER 2 OF 44 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:410432 CAPLUS
DOCUMENT NUMBER: 125:86487
TITLE: Preparation of N-[2-(1-pyrrolidinyl)-1-phenylethyl]acetamide as **kappa**-receptor agonists
INVENTOR(S): Ito, Fumitaka
PATENT ASSIGNEE(S): Pfizer Pharmaceuticals Inc., Japan
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9606078	A1	19960229	WO 1994-JP1399	19940824	<--
W: JP					
CA 2196885	AA	19960229	CA 1995-2196885	19950518	<--
CA 2196885	C	20010123			
WO 9606077	A1	19960229	WO 1995-IB374	19950518	<--
W: AU, CA, CN, CZ, FI, HU, JP, KR, MX, NO, NZ, PL, RU, US					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
AU 9523506	A1	19960314	AU 1995-23506	19950518	<--
EP 777649	A1	19970611	EP 1995-917437	19950518	
EP 777649	B1	19990714			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
JP 09510731	T2	19971028	JP 1995-529926	19950518	
JP 2935899	B2	19990816			
AT 182138	E	19990715	AT 1995-917437	19950518	
ES 2133767	T3	19990916	ES 1995-917437	19950518	
BR 9503775	A	19960416	BR 1995-3775	19950823	<--
FI 9700746	A	19970221	FI 1997-746	19970221	
US 5837720	A	19981117	US 1997-793225	19970417	

PRIORITY APPLN. INFO.: WO 1994-JP1399 A 19940824
WO 1995-IB374 W 19950518
OTHER SOURCE(S): MARPAT 125:86487
GI



I

AB The title compds. [I; R = hydrogen or hydroxy; A = (un)substituted Ph; X = (un)substituted Ph or heterocyclic, mono-, di- or tri-halomethyl, cyano, etc.; X1 = Ph, furyl, thienyl, pyridyl, thiazolyl, benzofuryl, benzothienyl, etc.], which have agonist activity toward opioid **kappa** receptors (no data) and are useful as analgesics (no data), antiinflammatory agents (no data), diuretics(no data), and neuroprotective agents (no data), are prepd. Thus, (2S,3S)-1-[2-N-(benzyloxycarbonyl)methylamino-2-phenylethyl]-3-hydroxypyrrolidine was condensed with 3,4-dichlorophenylacetyl chloride and the free base salified with HCl, producing the hydrochloride salt of N-(benzylcarbonyl)methyl-2-(3,4-dichlorophenyl)-N-[2-(3-(S)-hydroxypyrrolidin-1-yl)-1-(S)-phenylethyl]acetamide.

L10 ANSWER 15 OF 44 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 4
ACCESSION NUMBER: 1995:217334 CAPLUS
DOCUMENT NUMBER: 122:9806
TITLE: .**kappa**. Opioid Receptor Selective Affinity Labels: Electrophilic Benzeneacetamides as .**kappa**.-Selective Opioid Antagonists
AUTHOR(S): Chang, An-Chih; Takemori, Akira E.; Ojala, William H.; Gleason, William B.; Portoghese, Philip S.
CORPORATE SOURCE: College of Pharmacy, University of Minnesota, Minneapolis, MN, 55455, USA
SOURCE: Journal of Medicinal Chemistry (**1994**), 37(26), 4490-8
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Pyrrolidinylethylacetamides I [R = 3-, 4-NCS, (E)-NHCOCH:CHCO2Me] were synthesized as .**kappa**.-selective affinity labels and evaluated for opioid activity. In smooth muscle prepns., the non-electrophilic parent compd. (+)-S-I [R = H] and the affinity labels behaved as .**kappa**. agonists in that they were potently antagonized by norbinaltorphimine (norBNI). In addn. to the high binding affinity and selectivity of I [R = 3-NCS] to .**kappa**. opioid receptors, wash studies have suggested that this involves covalent binding. In the mouse tail-flick assay, I [R = NCS] produced long-lasting antagonism of the antinociceptive effect of the .**kappa**. opioid agonist, (.+-.)-trans-2-(3,4-dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]acetamide ((.+-.)-U50,488). In contrast, the non-electrophilic parent compd. (+)-S-I [R = H] and I [R = 3-(E)-NHCOCH:CHCO2Me] were devoid of antagonist activity in the tail-flick assay. At substantially different doses, I [R = 3-, 4-NCS] also produced antinociception in the mouse abdominal stretch assay. In addn., I [R = 3-NCS, 3-(E)-NHCOCH:CHCO2Me] had improved in vivo .**kappa**.-selectivities compared to (+)-S-I [R = H] and I [R = 4-(E)-NHCOCH:CHCO2Me]. The improved .**kappa**.-selectivities of I [R = 3-NCS, 3-(E)-NHCOCH:CHCO2Me] and the different agonist and antagonist potencies of I [R = 3-, 4-NCS] may be explained resp. by the existence of multiple .**kappa**. agonist binding sites and distinct agonist and antagonist binding sites. In view of the antagonist selectivity and the apparent irreversible binding of I [R = 3-NCS] to .**kappa**. receptors, it may serve as a useful pharmacol. or biochem. tool to investigate .**kappa**. opioid receptors.